Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study

Clin Nutr. 2020 Dec;39(12):3594-3600. doi: 10.1016/j.clnu.2020.03.007. Epub 2020 Mar 13.

Abstract

Background & aims: Chronic kidney disease (CKD) patients have numerous complications associated with inflammation, which is a potential driver for cardiovascular disease. Curcumin, a compound of the curcuminoid class produced by the Curcuma longa, has been reported to activate nuclear factor erythroid factor 2-related (Nrf2) and inhibit nuclear factor kappa-B (NF-kB). Our aim was to evaluate the effects of curcumin juice on the expression of inflammatory transcription factors in hemodialysis (HD) patients.

Methods and results: This double-blind randomized pilot study included 31 HD patients divided into two groups: curcumin group (receiving 100 mL of orange juice with 12 g of carrot and 2.5 g of turmeric after each dialysis session/week for 3 months) and control group (receiving the same juice without curcumin); 14 patients in each arm completed the study. The mRNA expression of Nrf2, NF-kB, NLRP3 inflammasome and IL-1β in peripheral blood mononuclear cells (PBMC; using real-time quantitative polymerase chain reaction, qPCR) and routine biochemistries, food intake and anthropometrics were analyzed. After three months of supplementation, the curcumin group showed a significant decrease in NF-kB mRNA expression (AU) [from 1.08 (0.77-1.38) to 0.52 (0.32-0.95),p = 0.02] and in plasma high sensitivity C-reactive protein (hsCRP) levels [from 3.8 (2.5-6.8) to 2.0 (1.1-3.8) mg/L, p = 0.04]. There was no change in the other evaluated markers.

Conclusion: Three months treatment with curcumin in CKD patients undergoing HD resulted in decreased markers of inflammation, NF-kB mRNA expression and hsCRP, suggesting that oral supplementation of curcumin may have an anti-inflammatory effect in this patient group.

Trial registration: Approved by the Ethics Committee of the Faculty of Medicine/UFF, number: 2.346.933. This study was registered within ClinicalTrials.gov under the number NCT03475017.

Keywords: Chronic kidney disease; Curcumin; Inflammation; Oxidative stress; Turmeric.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents / administration & dosage
  • Antioxidants / administration & dosage
  • Biomarkers / blood
  • C-Reactive Protein / analysis
  • Curcumin / administration & dosage*
  • Daucus carota*
  • Dietary Supplements*
  • Double-Blind Method
  • Female
  • Fruit and Vegetable Juices*
  • Humans
  • Interleukin-1beta / blood
  • Leukocytes, Mononuclear / metabolism
  • Longitudinal Studies
  • Male
  • Middle Aged
  • NF-E2-Related Factor 2 / blood
  • NF-kappa B / blood
  • NLR Family, Pyrin Domain-Containing 3 Protein / blood
  • Oxidative Stress
  • Pilot Projects
  • Renal Dialysis / adverse effects
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / therapy*
  • Transcription Factors / blood*

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Biomarkers
  • IL1B protein, human
  • Interleukin-1beta
  • NF-E2-Related Factor 2
  • NF-kappa B
  • NFE2L2 protein, human
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human
  • Transcription Factors
  • C-Reactive Protein
  • Curcumin

Associated data

  • ClinicalTrials.gov/NCT03475017